Liquidia (NASDAQ:LQDA) CAO Sells $643,733.02 in Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 9,002 shares of the company’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $643,733.02. Following the transaction, the chief accounting officer directly owned 169,519 shares of the company’s stock, valued at $12,122,303.69. This represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, April 27th, Dana Boyle sold 1,576 shares of Liquidia stock. The stock was sold at an average price of $37.78, for a total value of $59,541.28.

Liquidia Stock Up 7.4%

Liquidia stock traded up $5.28 during midday trading on Tuesday, reaching $76.49. The stock had a trading volume of 1,153,916 shares, compared to its average volume of 2,219,263. The stock has a market capitalization of $6.80 billion, a P/E ratio of 546.40 and a beta of 0.55. The firm’s fifty day simple moving average is $66.37 and its 200-day simple moving average is $47.52. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. Liquidia Corporation has a 1-year low of $14.04 and a 1-year high of $82.96.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company’s revenue for the quarter was up 4187.1% on a year-over-year basis. As a group, analysts expect that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia during the fourth quarter worth $25,000. NewEdge Advisors LLC bought a new stake in Liquidia during the second quarter worth $25,000. FNY Investment Advisers LLC acquired a new stake in Liquidia in the third quarter valued at $34,000. Covestor Ltd lifted its stake in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Liquidia by 281.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after acquiring an additional 4,927 shares during the period. 64.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on LQDA. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Raymond James Financial restated a “strong-buy” rating and set a $68.00 price objective on shares of Liquidia in a research note on Thursday, June 4th. Oppenheimer set a $75.00 price objective on Liquidia in a report on Friday, June 5th. HC Wainwright lifted their target price on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. Finally, Needham & Company LLC upped their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).